Resverlogix Corp. (RVX.TO)
CAD 0.05
(12.5%)
CAD 0.05
(12.5%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 | -3.61 Million USD | 85.43% |
| 2021 | -24.77 Million USD | -1005212.6% |
| 2020 | 2464.50 USD | -100.0% |
| 2019 | 118.02 Million USD | 72597.82% |
| 2018 | -162.79 Thousand USD | 99.72% |
| 2017 | -58.31 Million USD | -26.18% |
| 2016 | -46.21 Million USD | -134.39% |
| 2015 | -19.71 Million USD | -207.6% |
| 2014 | 18.32 Million USD | 133.25% |
| 2013 | -55.1 Million USD | -227.1% |
| 2012 | 43.35 Million USD | 330.83% |
| 2011 | -18.78 Million USD | 15.09% |
| 2010 | -22.12 Million USD | 19.46% |
| 2009 | -27.46 Million USD | -51.73% |
| 2008 | -18.1 Million USD | 35.64% |
| 2007 | -28.12 Million USD | -69.97% |
| 2006 | -16.54 Million USD | -159.22% |
| 2005 | -6.38 Million USD | -124.99% |
| 2004 | -2.83 Million USD | -101.11% |
| 2003 | -1.41 Million USD | -175.11% |
| 2002 | -512.82 Thousand USD | -1208.95% |
| 2001 | -39.17 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q1 | -5155.00 USD | -100.64% |
| 2023 Q2 | -4.01 Million USD | -77766.15% |
| 2023 Q3 | -4.44 Million USD | -10.81% |
| 2022 Q1 | -2.33 Million USD | 86.2% |
| 2022 Q2 | -403 Thousand USD | 82.72% |
| 2022 Q3 | -1.67 Million USD | -315.88% |
| 2022 FY | -3.61 Million USD | 85.43% |
| 2022 Q4 | 801 Thousand USD | 147.79% |
| 2021 Q2 | -2.6 Million USD | -13145.0% |
| 2021 Q1 | 20 Thousand USD | 0.0% |
| 2021 FY | -24.77 Million USD | -1005212.6% |
| 2021 Q4 | -16.89 Million USD | -219.64% |
| 2021 Q3 | -5.28 Million USD | -102.61% |
| 2020 Q3 | -3.42 Million USD | 44.91% |
| 2020 FY | 2464.50 USD | -100.0% |
| 2020 Q1 | 8.72 Million USD | 86.39% |
| 2020 Q2 | -6.2 Million USD | -171.18% |
| 2019 Q4 | 4.67 Million USD | -95.35% |
| 2019 Q3 | 100.66 Million USD | 2442.71% |
| 2019 Q2 | 3.95 Million USD | 106.52% |
| 2019 Q1 | -60.69 Million USD | -352.77% |
| 2019 FY | 118.02 Million USD | 72597.82% |
| 2018 Q3 | -39.2 Million USD | 20.79% |
| 2018 Q4 | -13.4 Million USD | 65.8% |
| 2018 Q1 | -8.2 Million USD | 65.62% |
| 2018 Q2 | -49.49 Million USD | -503.03% |
| 2018 FY | -162.79 Thousand USD | 99.72% |
| 2017 FY | -58.31 Million USD | -26.18% |
| 2017 Q4 | -23.87 Million USD | -119.51% |
| 2017 Q3 | -10.87 Million USD | 29.18% |
| 2017 Q2 | -15.35 Million USD | -32.72% |
| 2017 Q1 | -11.57 Million USD | 10.97% |
| 2016 Q3 | -15.16 Million USD | -134.06% |
| 2016 Q1 | -9.67 Million USD | -9.06% |
| 2016 Q2 | -6.47 Million USD | 33.06% |
| 2016 FY | -46.21 Million USD | -134.39% |
| 2016 Q4 | -12.99 Million USD | 14.31% |
| 2015 Q3 | -3.8 Million USD | -243.97% |
| 2015 Q4 | -8.87 Million USD | -133.25% |
| 2015 FY | -19.71 Million USD | -207.6% |
| 2015 Q2 | 2.64 Million USD | -84.17% |
| 2015 Q1 | 16.69 Million USD | 1107.66% |
| 2014 Q1 | -370 Thousand USD | 97.58% |
| 2014 FY | 18.32 Million USD | 133.25% |
| 2014 Q3 | -3.33 Million USD | 49.58% |
| 2014 Q4 | -1.65 Million USD | 50.37% |
| 2014 Q2 | -6.62 Million USD | -1689.73% |
| 2013 FY | -55.1 Million USD | -227.1% |
| 2013 Q3 | 1.92 Million USD | 104.65% |
| 2013 Q4 | -15.28 Million USD | -893.82% |
| 2013 Q2 | -41.37 Million USD | -436.99% |
| 2013 Q1 | 12.27 Million USD | -4.22% |
| 2012 FY | 43.35 Million USD | 330.83% |
| 2012 Q4 | 12.82 Million USD | 224.43% |
| 2012 Q3 | -10.3 Million USD | -29.53% |
| 2012 Q2 | -7.95 Million USD | -16.24% |
| 2012 Q1 | -6.84 Million USD | -2.87% |
| 2011 Q4 | -6.65 Million USD | -52.01% |
| 2011 FY | -18.78 Million USD | 15.09% |
| 2011 Q2 | -912 Thousand USD | 86.51% |
| 2011 Q3 | -4.37 Million USD | -379.82% |
| 2011 Q1 | -6.76 Million USD | -49.96% |
| 2010 Q3 | -5.31 Million USD | -0.14% |
| 2010 Q4 | -4.5 Million USD | 15.21% |
| 2010 FY | -22.12 Million USD | 19.46% |
| 2010 Q1 | -9.84 Million USD | -20.68% |
| 2010 Q2 | -5.31 Million USD | 46.03% |
| 2009 Q2 | -5.06 Million USD | -21.72% |
| 2009 Q4 | -8.15 Million USD | -88.77% |
| 2009 Q3 | -4.31 Million USD | 14.64% |
| 2009 Q1 | -4.15 Million USD | 21.0% |
| 2009 FY | -27.46 Million USD | -51.73% |
| 2008 Q3 | -4.62 Million USD | 8.08% |
| 2008 Q1 | -7.05 Million USD | -13.24% |
| 2008 Q2 | -5.03 Million USD | 28.69% |
| 2008 Q4 | -5.26 Million USD | -13.74% |
| 2008 FY | -18.1 Million USD | 35.64% |
| 2007 Q2 | -6.56 Million USD | 20.91% |
| 2007 Q4 | -6.23 Million USD | 25.05% |
| 2007 Q3 | -8.31 Million USD | -26.78% |
| 2007 Q1 | -8.29 Million USD | -113.88% |
| 2007 FY | -28.12 Million USD | -69.97% |
| 2006 FY | -16.54 Million USD | -159.22% |
| 2006 Q4 | -3.87 Million USD | -37.48% |
| 2006 Q3 | -2.82 Million USD | -59.83% |
| 2006 Q1 | -2.05 Million USD | -58.25% |
| 2006 Q2 | -1.76 Million USD | 14.1% |
| 2005 Q2 | -1.12 Million USD | -22.43% |
| 2005 FY | -6.38 Million USD | -124.99% |
| 2005 Q4 | -1.29 Million USD | 26.69% |
| 2005 Q3 | -1.77 Million USD | -57.83% |
| 2005 Q1 | -916.5 Thousand USD | 0.17% |
| 2004 Q4 | -918.04 Thousand USD | -70.04% |
| 2004 Q2 | -440.22 Thousand USD | 39.68% |
| 2004 Q1 | -729.77 Thousand USD | -213.3% |
| 2004 FY | -2.83 Million USD | -101.11% |
| 2004 Q3 | -539.89 Thousand USD | -22.64% |
| 2003 Q3 | -146.28 Thousand USD | 48.73% |
| 2003 Q2 | -285.33 Thousand USD | -14.94% |
| 2003 FY | -1.41 Million USD | -175.11% |
| 2003 Q4 | -232.92 Thousand USD | -59.23% |
| 2003 Q1 | -248.24 Thousand USD | -110.21% |
| 2002 Q3 | -12.95 Thousand USD | 49.44% |
| 2002 Q4 | -118.09 Thousand USD | -811.58% |
| 2002 FY | -512.82 Thousand USD | -1208.95% |
| 2002 Q1 | -4777.27 USD | 0.0% |
| 2002 Q2 | -25.62 Thousand USD | -436.37% |
| 2001 FY | -39.17 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Appili Therapeutics Inc. | -3.78 Million CAD | 4.52% |
| Eupraxia Pharmaceuticals Inc. | -37.39 Million CAD | 90.345% |
| Helix BioPharma Corp. | -9.26 Million CAD | 61.032% |
| Microbix Biosystems Inc. | -39.48 Thousand CAD | -9043.176% |
| Medicenna Therapeutics Corp. | -25.46 Million CAD | 85.824% |
| Satellos Bioscience Inc. | -15.88 Million CAD | 77.28% |
| Oncolytics Biotech Inc. | -27.75 Million CAD | 86.992% |
| Sernova Corp. | -38.99 Million CAD | 90.743% |